Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2022-04-28 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
独立董事关于第八届董事局第二十七次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors regarding their prior approval opinions on agenda items for the 27th meeting of the 8th board of directors of Shenzhen Haier Bioengineering Co., Ltd. The agenda includes the proposal to renew the appointment of the 2022 audit firm and the proposal on expected daily related party transactions for 2022. The document is a governance-related opinion and approval statement by independent directors, referencing corporate governance rules and regulatory guidelines. It does not contain financial statements or audit reports themselves, nor is it an announcement of voting results or a report publication. It is related to board/management information, specifically the independent directors' opinions on board meeting matters.
2022-04-28 Chinese
年度股东大会通知
AGM Information Classification · 100% confidence The document is a detailed announcement regarding the convening of the 2021 Annual General Meeting (AGM) of Shenzhen Haier Bioengineering Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be discussed, and instructions for shareholders to participate either in person or via online voting. The document does not contain the actual annual report or financial statements but rather the notice and procedural details for the AGM. The document length is 4230 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2022-04-28 Chinese
2021年年度财务报告
Annual Report Classification · 100% confidence The document is titled "深圳市海王生物工程股份有限公司 2021 年年度财务报告" which translates to "Shenzhen Haiwang Bioengineering Co., Ltd. 2021 Annual Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, and notes. It also includes an audit report with an unqualified opinion from a registered accounting firm dated April 27, 2022. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. The content includes comprehensive financial data and audit opinions for the full fiscal year 2021. This matches the definition of an Annual Report (10-K) which covers the company's yearly activity and full financial performance. Therefore, the document should be classified as an Annual Report (10-K). FY 2021
2022-04-28 Chinese
2022年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '深圳市海王生物工程股份有限公司 2022 年第一季度报告全文' which translates to 'Shenzhen Haier Bioengineering Co., Ltd. 2022 First Quarter Report Full Text'. It contains detailed financial data including income statement, balance sheet, cash flow statement, and notes for the first quarter of 2022. It explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. The document also mentions that the report is unaudited, which is common for interim/quarterly reports. There is no indication that this is an announcement or a summary; it is the full report itself. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2022-04-28 Chinese
2021年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2021 Annual Report" of Shenzhen Neptunus Bioengineering Co., Ltd. It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, corporate governance, social responsibility, shareholding information, and full financial statements. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of audited financial statements and management's discussion confirms it is a comprehensive yearly report covering company activity and financial performance for the fiscal year 2021. Therefore, the document fits the definition of an Annual Report (10-K). FY 2021
2022-04-28 Chinese
关于筹划重大事项的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the progress of planning a major transaction, specifically a major asset restructuring and mixed-ownership reform by the controlling shareholder. It mentions that the matter is still in the preliminary investigation and due diligence phase, with no formal agreements signed yet. The document emphasizes risk warnings and ongoing compliance with disclosure obligations. There are no financial statements or detailed financial data presented, nor is this a full report or earnings release. The content fits the description of a Capital/Financing Update (CAP) as it relates to updates on company fundraising, financing activities, or capital structure changes. The document length is short (997 characters), but it contains substantive update information rather than just announcing a report publication. Therefore, the best classification is CAP with high confidence.
2022-04-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.